On Air Now

Listen

Listen Live Now » 93.7 FM Sheboygan, WI

Weather

Current Conditions(Sheboygan,WI 53081)

More Weather »
40° Feels Like: 34°
Wind: S 8 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Showers 45°

Tonight

Rain 40°

Tomorrow

AM Showers 59°

Alerts

FDA grants priority review status to Gilead's hepatitis C drug

(Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

The FDA set a review date of December 8 for the drug, Gilead said.

Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.

Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.

(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)

Comments